RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In Vitro

- Oral opaganib's reported potent in vitro activity against Omicron adds to previously observed inhibition of Delta and other SARS-CoV-2 variants of concern...

Related Keywords

United Kingdom ,Israel ,Michael Chan ,Amber Fennell ,Redhill Biopharma ,Reza Fathi ,Adi Frish ,Us National Institute Of Health ,University Of Hong Kong ,School Of Public Health ,Redhill Biopharma Ltd ,Nasdaq ,Exchange Commission ,Company Annual Report On Form ,Company Expanded Access Program ,Centre For Immunology ,Corporate Business Development ,Prnewswire Redhill Biopharma Ltd ,Hong Kong School ,Public Health ,Hill Biopharma ,Hong Kong ,Principal Investigator ,Hazard Ratio ,Orphan Drug ,Private Securities Litigation Reform Act ,Expanded Access Program ,Annual Report ,